TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response.

TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response.

Item
http://www.wikidata.org/entity/Q40172029
Mining gene expression data of multiple sclerosisEndogenous and recombinant type I interferons and disease activity in multiple sclerosisExcessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosisEarly detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes.Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties.Implications of Lymphocyte Anergy to Glycolipids in Multiple Sclerosis (MS): iNKT Cells May Mediate the MS Infectious Trigger.Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patientsTRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic responseInterferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Flu-like symptoms and associated immunological response following therapy with botulinum toxins.TRAIL gene expression analysis in multiple sclerosis patients.
P2860

TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response.

Item
http://www.wikidata.org/entity/Q40172029
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
TRAIL, CXCL10 and CCL2 plasma ...... predict therapeutic response.
@en
type
label
TRAIL, CXCL10 and CCL2 plasma ...... predict therapeutic response.
@en
prefLabel
TRAIL, CXCL10 and CCL2 plasma ...... predict therapeutic response.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
TRAIL, CXCL10 and CCL2 plasma ...... t predict therapeutic response
@en
P2093
P304
P31
P356
10.1016/J.JNEUROIM.2007.08.009
P433
P478
P50
P577
P698
P921